Cost-effective osteoporosis treatment thresholds: the United States perspective
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Unlabelled A United States-specific cost-effectiveness analysis, which incorporated the cost and health consequences of clinical fractures of the hip, spine, forearm, shoulder, rib, pelvis and lower leg, was undertaken to identify the 10-year hip fracture probability required for osteoporosis treatment to be cost-effective for cohorts defined by age, sex, and race/ethnicity. A 3% 10-year risk of hip fracture was generally required for osteoporosis treatment to cost less than $60,000 per QALY gained. Introduction Rapid growth of the elderly United States population will result in so many at risk of osteoporosis that economically efficient approaches to osteoporosis care warrant consideration. Methods A Markov-cohort model of annual United States age-specific incidence of clinical hip, spine, forearm, shoulder, rib, pelvis and lower leg fractures, costs (2005 US dollars), and quality-adjusted life years (QALYs) was used to assess the cost-effectiveness of osteoporosis treatment ($600/yr drug cost for 5 years with 35% fracture reduction) by gender and race/ethnicity groups. To determine the 10-year hip fracture probability at which treatment became cost-effective, average annual age-specific probabilities for all fractures were multiplied by a relative risk (RR) that was systematically varied from 0 to 10 until a cost of $60,000 per QALY gained was observed for treatment relative to no intervention. Results Osteoporosis treatment was cost-effective when the 10-year hip fracture…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The latter analyses generally confirm the previous NOF conclusion that it is cost-effective to treat individuals with a prior hip or vertebral fracture and those with a DXA femoral neck T-score ≤−2.5.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [12]
In the citing paper
“The latter analyses generally confirm the previous NOF conclusion that it is cost-effective to treat individuals with a prior hip or vertebral fracture and those with a DXA femoral neck T-score ≤−2.5.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [12]
In the citing paper
“Therapeutic intervention thresholds are based on NOF’s economic analysis that takes into consideration the cost-effectiveness of treatments and competition for resources in the USA [12, 13].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [12]
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Self-citationEpidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821 · cited 2×
“Although osteoporotic fractures are less common among non-white populations and men [14], it was assumed that, should a fracture occur, the associated reduction in quality of life would be the same as for a postmenopausal white woman.”
BackgroundMethodSelf-citationMarkov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419
A meta-analysis of previous fracture and subsequent fracture risk
Kanis, J. A., Johnell, O., De Laet, C., Johansson, H., Oden, A., Delmas, P., Eisman, J., Fujiwara, S., Garnero, P., Kroger, H., et al. (2004) · Bone · doi:10.1016/j.bone.2004.03.024 · Cited by 1,278
Self-citationKanis, J. A., Borgstrom, F., De Laet, C., Johansson, H., Johnell, O., Jonsson, B., Oden, A., Zethraeus, N., Pfleger, B., & Khaltaev, N. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1780-5 · Cited by 1,233
Population-Based Study of Survival after Osteoporotic Fractures
Cooper, C., Atkinson, E. J., Jacobsen, S. J., O’Fallon, W. M., & Melton, L. J. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116756 · Cited by 1,100 · cited 1×
“Substantial mortality has been reported among patients in the year following hip fracture [24–31].”
BackgroundSelf-citationMortality and morbidity after hip fractures.
Keene, G. S., Parker, M. J., & Pryor, G. A. (1993) · BMJ · doi:10.1136/bmj.307.6914.1248 · Cited by 876
The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds
Kanis, J. A., Oden, A., Johnell, O., Jonsson, B., de Laet, C., & Dawson, A. (2001) · Osteoporosis International · doi:10.1007/s001980170112 · Cited by 726 · cited 1×
“For women, other fractures included proximal humerus, rib, pelvis, and tibia/ fibula; tibia/fibula fractures were excluded for men as described elsewhere [7].”
BackgroundII. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-2002 · Cited by 445
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA
Dawson-Hughes, B., Tosteson, A. N. A., Melton, L. J., Baim, S., Favus, M. J., Khosla, S., & Lindsay, R. L. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0559-5 · Cited by 427 · cited 3×
“Application of the WHO risk prediction tool to identify individuals who meet the intervention thresholds, as detailed in the accompanying paper [35], should facilitate identification of appropriate individuals for treatment and will help optimize efficient osteoporosis care.”
BackgroundMethodInfluentialSelf-citationAdverse Outcomes of Osteoporotic Fractures in the General Population
Melton, L. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1139 · Cited by 423 · cited 1×
“This is because the excess mortality following vertebral fractures is late, not early, and there is no consistent pattern of excess mortality following fractures at the other skeletal sites [23].”
BackgroundSelf-citationHanmer, J., Lawrence, W. F., Anderson, J. P., Kaplan, R. M., & Fryback, D. G. (2006) · Medical Decision Making · doi:10.1177/0272989x06290497 · Cited by 395 · cited 1×
“The health state values expected for each age-group and sex were derived from EuroQol EQ-5D based on United States population data [20].”
MethodMelton III, L. J., Crowson, C. S., & O'Fallon, W. M. (1999) · Osteoporosis International · doi:10.1007/s001980050113 · Cited by 385 · cited 1×
“Thus, to validate the model structure, both approaches were undertaken and compared using data on sex- and age-specific fracture incidence either overall (Approach 1) or for first fracture (Approach 2) as taken from Olmsted County, MN [12], which is disproportionately white (90% in 2005) [13].”
MethodSelf-citationSurvival and ambulation following hip fracture.
Miller, C. W. (1978) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-197860070-00010 · Cited by 372 · cited 1×
“Substantial mortality has been reported among patients in the year following hip fracture [24–31].”
BackgroundA New Approach to the Development of Assessment Guidelines for Osteoporosis
Kanis, J. A., Black, D., Cooper, C., Dargent, P., Dawson-Hughes, B., De Laet, C., Delmas, P., Eisman, J., Johnell, O., Jonsson, B., et al. (2002) · Osteoporosis International · doi:10.1007/s001980200069 · Cited by 338 · cited 1×
“Instead, we follow the approach taken in European guidelines development [2] of focusing on when treatment is warranted while leaving particular treatment choices up to individual clinicians and patients.”
BackgroundSelf-citationArias, E., Anderson, R. N., Kung, H.-C., Murphy, S. L., & Kochanek, K. D. (2003) · PubMed · Cited by 313
Excess mortality attributable to hip fracture in white women aged 70 years and older.
Magaziner, J., Lydick, E., Hawkes, W., Fox, K. M., Zimmerman, S. I., Epstein, R. S., & Hebel, J. R. (1997) · American Journal of Public Health · doi:10.2105/ajph.87.10.1630 · Cited by 259 · cited 1×
“Substantial mortality has been reported among patients in the year following hip fracture [24–31].”
BackgroundThe risk and burden of vertebral fractures in Sweden
Kanis, J. A., Johnell, O., Oden, A., Borgstrom, F., Zethraeus, N., De Laet, C., & Jonsson, B. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1463-7 · Cited by 241 · cited 1×
“[41].”
Determinants of Reduced Survival Following Hip Fractures in Men
Poór, G., Atkinson, E. J., O'Fallon, W. M., & Melton, L. J. (1995) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199510000-00028 · Cited by 236 · cited 1×
“Although hip fracture may often be the precipitating event causing death, serious underlying diseases are quite common in this group [5, 29].”
BackgroundSelf-citationDirect Medical Costs Attributable to Osteoporotic Fractures
Gabriel, S. E., Gabriel, S. E., Tosteson, A. N. A., Leibson, C. L., Crowson, C. S., Pond, G. R., Hammond, C. S., & Melton, III (2002) · Osteoporosis International · doi:10.1007/s001980200033 · Cited by 232 · cited 2×
“incremental expenditures, compared to controls, in the year following versus the year before fracture [21].”
BackgroundSelf-citationHip Fracture Incidence and Mortality in New England
Fisher, E. S., Baron, J. A., Malenka, D. J., Barrett, J. A., Kniffin, W. D., Whaley, F. S., & Bubolz, T. A. (1991) · Epidemiology · doi:10.1097/00001648-199103000-00005 · Cited by 190
HAENTJENS, P., AUTIER, P., COLLINS, J., VELKENIERS, B., VANDERSCHUEREN, D., & BOONEN, S. (2003) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200310000-00011 · Cited by 182 · cited 1×
“higher rate based on evidence from metaanalyses that have addressed this question [10, 11].”
BackgroundCost-effectiveness of Bone Densitometry Followed by Treatment of Osteoporosis in Older Men
Schousboe, J. T., Taylor, B. C., Fink, H. A., Kane, R. L., Cummings, S. R., Orwoll, E. S., Melton, L. J., Bauer, D. C., & Ensrud, K. E. (2007) · JAMA · doi:10.1001/jama.298.6.629 · Cited by 170 · cited 1×
“A more recent analysis addressed these issues in men and found it reasonably cost-effective to screen men age 65 and older with a history of prior fracture [37].”
BackgroundSelf-citationBorgström, F., Johnell, O., Kanis, J. A., Jönsson, B., & Rehnberg, C. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0107-0 · Cited by 138 · cited 6×
“, approximately $75,000 for the United States) that was recently advocated as a reasonable cost-effectiveness criterion [16].”
BackgroundInfluentialIntervention thresholds for osteoporosis in the UK
Kanis, J. А., Borgström, F., Zethraeus, N., Johnell, O., Odén, A., & Jönsson, B. (2004) · Bone · doi:10.1016/j.bone.2004.08.018 · Cited by 129
Long-Term Trends in Hip Fracture Prevalence: The Influence of Hip Fracture Incidence and Survival
Melton, L. J., Therneau, T. M., & Larson, D. R. (1998) · Osteoporosis International · doi:10.1007/s001980050050 · Cited by 128
Self-citationIntervention thresholds for osteoporosis in men and women: a study based on data from Sweden
Kanis, J. А., Johnell, O., Odén, A., Borgström, F., Johansson, H., Laet, C. E. D. H. D., & Jönsson, B. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1623-4 · Cited by 113 · cited 7×
“Although this does not match the efficacy profile for any specific agent, it is well within the range of values that are reasonable for bisphosphonate treatment and has the added advantage of allowing comparison with European efforts to identify intervention thresholds [8, 9, 16].”
BackgroundMethodResultInfluentialCost-utility analyses of clinical preventive services
Stone, P. W., Teutsch, S., Chapman, R. H., Bell, C., Goldie, S. J., & Neumann, P. J. (2000) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(00)00151-3 · Cited by 111
Challenges for Model-Based Economic Evaluations of Postmenopausal Osteoporosis Interventions
Tosteson, A. N. A., Jönsson, B., Grima, D. T., O'Brien, B. J., Black, D. M., & Adachi, J. D. (2001) · Osteoporosis International · doi:10.1007/s001980170036 · Cited by 103 · cited 1×
“Treatment effectiveness was allowed to deteriorate following discontinuation of therapy and was assumed to be fully offset 5 years after discontinuation as recommended elsewhere [17].”
BackgroundSelf-citationSchousboe, J. T., Ensrud, K. E., Nyman, J. A., Melton, L. J., & Kane, R. L. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53504.x · Cited by 94 · cited 1×
“no intervention) in older white women in this country highlighted the potential value of screen and treat strategies [36].”
BackgroundSelf-citationHealth status before and mortality after hip fracture.
Katelaris, A., & Cumming, R. G. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.4.557 · Cited by 80 · cited 1×
“Substantial mortality has been reported among patients in the year following hip fracture [24–31].”
BackgroundAddressing Resource Allocation Issues in Recommendations From Clinical Practice Guideline Panels
Guyatt, G. H., Baumann, M. H., Pauker, S. G., Halperin, J. L., MAURER, J. R., Owens, D. K., Tosteson, A. N. A., Carlin, B. W., Gutterman, D. D., Prins, M. H., et al. (2006) · CHEST Journal · doi:10.1378/chest.129.1.182 · Cited by 54 · cited 1×
“Cost consideration in clinical guidelines development is sometimes controversial [40].”
BackgroundSelf-citationKing, A. B., Saag, K. G., Burge, R. T., Pisu, M., & Goel, N. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1869-5 · Cited by 45 · cited 1×
“Other United States studies have shown the potential for clinical strategies involving bone densitometry to be cost-saving [38, 39].”
BackgroundBadamgarav, E., & Fitzpatrick, L. A. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1009 · Cited by 26 · cited 1×
“Although studies indicate that early discontinuation with treatment is common [18], the baseline assumption of 100% persistence over the 5-year treatment period reflects an optimistic assessment of the economic value of osteoporosis treatment.”
BackgroundEconomic comparison of diagnostic approaches for evaluating osteoporosis in older women
Kraemer, D. F., Nelson, H. D., Bauer, D. C., & Helfand, M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1922-4 · Cited by 21 · cited 1×
“Other United States studies have shown the potential for clinical strategies involving bone densitometry to be cost-saving [38, 39].”
BackgroundCharacterizing preferences for health outcomes in economic evaluations.
Tosteson, A. N. A. (2003) · PubMed · Cited by 1
Self-citation
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
“Several studies have examined the costeffectiveness of intervention thresholds expressed in terms of fracture probability [109, 110, 117, 122, 285, 286].”
BackgroundEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“Several studies have examined the costeffectiveness of intervention thresholds expressed in terms of fracture probability [123, 127, 130, 360, 361].”
BackgroundPapaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
“5) should be treated when the 10-year risk of hip fracture is ≥ 3% or the 10-year risk of major osteoporosis-related fracture is ≥ 20%.(67) The National Osteoporosis Guideline Group recommends an age-dependent intervention threshold, which ranges from 7.”
BackgroundThe clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Metadata
- Authors
- Tosteson, A. N. A., Melton, L. J., Dawson-Hughes, B., Baim, S., Favus, M. J., Khosla, S., & Lindsay, R. L.
- Affiliations
- Dartmouth Institute for Health Policy and Clinical Practice (US)
- Mayo Clinic (US)
- Medical College of Wisconsin (US)
- University of Chicago (US)
- Helen Hayes Hospital (US)
- Corresponding author
- Tosteson, A. N. A.
- Venue
- Osteoporosis International
- Published
- 2008-02-22
- Volume
- 19
- Issue
- 4
- Pages
- 437-447
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC2729707
- OpenAlex
- W2144832496
- Cited by
- 441
- References
- 38
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 8 · 2023: 16 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 19 · 2018: 21 · 2017: 14 · 2016: 21 · 2015: 26 · 2014: 21 · 2013: 29 · 2012: 40
- FWCI
- 49.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p60ar048094-05)
- National Institute on Aging (AG12262, R01AG012262)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR048094, P60-AR048094)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis treatment, cost-effectiveness, hip fracture, fracture risk prediction, quality-adjusted life years, sex differences, racial and ethnic differences, older adults, treatment thresholds
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Algorithms, Cost-Benefit Analysis, Female, Humans, Male, Middle Aged, Osteoporosis, Probability, Time Factors, United States, Health Care Costs, Models, Economic, Quality-Adjusted Life Years, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.